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Abstract
Background: Multiple factors, including interactions between genetic and environmental risks, are important in
susceptibility to rheumatoid arthritis (RA). However, the underlying mechanism is not fully understood. This study
was undertaken to evaluate whether DNA methylation can mediate the interaction between genotype and
smoking in the development of anti-citrullinated peptide antibody (ACPA)-positive RA.
Methods: We investigated the gene-smoking interactions in DNA methylation using 393 individuals from the
Epidemiological Investigation of Rheumatoid Arthritis (EIRA). The interaction between rs6933349 and smoking in
the risk of developing ACPA-positive RA was further evaluated in a larger portion of the EIRA (1119 controls and
944 ACPA-positive patients with RA), and in the Malaysian Epidemiological Investigation of Rheumatoid Arthritis
(MyEIRA) (1556 controls and 792 ACPA-positive patients with RA). Finally, mediation analysis was performed to
investigate whether DNA methylation of cg21325723 mediates this gene-environment interaction on the risk of
developing of ACPA-positive RA.
Results: We identified and replicated one significant gene-environment interaction between rs6933349 and
smoking in DNA methylation of cg21325723. This gene-smoking interaction is a novel interaction in the risk of
developing ACPA-positive in both Caucasian (multiplicative P value = 0.056; additive P value = 0.016) and Asian
populations (multiplicative P value = 0.035; additive P value = 0.00027), and it is mediated through DNA methylation
of cg21325723.
Conclusions: We showed that DNA methylation of cg21325723 can mediate the gene-environment interaction
between rs6933349 and smoking, impacting the risk of developing ACPA-positive RA, thus being a potential
regulator that integrates both internal genetic and external environmental risk factors.
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Background
Rheumatoid arthritis (RA) is a chronic autoimmune
disease that leads to inflammation of the joints and sur-
rounding tissues. It can cause severe functional disabil-
ities, pain, and other disorders, such as cardiovascular
disease. RA is a complex inflammatory disease affecting
up to 1% of the population. The fact that the concord-
ance rate for RA in monozygotic twins is less than 20%
suggests that environmental factors may be highly in-
volved in the etiology of the disease. In recent decades,
it has been shown that the two major subgroups of RA,
anti-citrullinated peptide antibody (ACPA)-positive and
ACPA-negative RA, have in part different etiology. One
example of this is the shared epitope (SE) alleles of the
human leukocyte antigen DR beta chain 1 (HLA-
DRB1), which is a major risk factor for ACPA-positive
RA, but not to the same extent for ACPA-negative RA.
Environmental/lifestyle factors, such as smoking [1–3]
and other noxious airway exposures [4, 5], have been
shown to be risk factors for RA, mainly for the ACPA-
positive subset of RA.
Smoking is a well-studied risk factor for RA and for
the severity of RA [6–8]. There is a dose-dependent
interaction between smoking and variations in the HLA-
DRB1 gene in the risk of developing ACPA-positive RA
[9, 10]. One hypothesis proposed for the etiology of
ACPA-positive RA is that the autoantibodies (ACPA)
that are directed against citrullinated proteins in the
joints originate from the mucosal tissues, e.g. the lungs,
exposed to harmful inhaled toxicants such as smoking
or silica dust. However, there remains a challenge to
fully understand the molecular mechanism of the gene-
environment interaction in the pathogenesis RA.
Epigenetic modifications, such as DNA methylation,
have an important role in controlling when and where
genes are expressed, and can be influenced by environ-
mental factors. Such epigenetic modifications may thus
provide a possible biological link between environmental
exposures, genetic variations, and the disease. In fact,
smoking has also been demonstrated to perturb DNA
methylation signatures in lymphocytes [11]. Moreover,
there is also growing evidence that epigenetic modifica-
tions can be controlled by the DNA sequence, and can
be a mediator of genetic risk in common diseases, such
as RA [12] and allergy [13]. Thus, it is relevant to investi-
gate whether DNA methylation can mediate the interac-
tions between genotype and smoking in the development
of ACPA-positive RA (Fig. 1a) and whether it is a regula-
tor that can integrate both internal genetic and external
environmental risk factors.
In this report, by using data from multiple cohorts
(Fig. 1b) we evaluated whether DNA methylation can
mediate the interaction between genotype and smoking
in the development of ACPA-positive RA.
Methods
Subjects
The EIRA (Epidemiological Investigation of Rheumatoid
Arthritis) is a Swedish population-based case-control
study. Recruitment of patients with RA in the EIRA
study was described previously [14], and the healthy
controls were selected from the same population to
match the RA cases by age, sex and residential area at
the time of diagnosis. Self-reported smoking habits
were registered from the EIRA questionnaire. The
genotyping and its quality control (QC) procedures
have been described previously [14], and imputation
was done using the IMPUTE2 algorithm [15] based on
the phased 1000 genome reference set (March 2012
haplotypes). This group of samples with information on
genotype, methylation, and smoking status was used for
the investigation of genotype and smoking interaction
in DNA methylation.
The EIMS (Epidemiological Investigation of risk fac-
tors for Multiple Sclerosis) is a population-based case-
control study comprising Swedish-speaking subjects in
Sweden and details of the recruitment procedure were
described previously [16]. Briefly, newly diagnosed pa-
tients with multiple sclerosis (MS) were recruited via
40 study centers in Sweden and healthy controls were
randomly selected from the national population regis-
ter, matched by age, sex, and residential area. Self-
reported smoking information was registered from the
EIMS questionnaire.
Fig. 1 Study model (a) and work flow diagram (b). ACPA anti-
citrullinated peptide antibodies, RA rheumatoid arthritis, EIRA
Epidemiological Investigation of Rheumatoid Arthritis, EIMS
Epidemiological Investigation of Multiple Sclerosis, MyEIRA Malaysian
Epidemiological Investigation of Rheumatoid Arthritis
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The MyEIRA (Malaysian Epidemiological Investiga-
tion of Rheumatoid Arthritis) is another independent
population-based case-control study, in which the sub-
jects were recruited in Peninsular Malaysia with three
major ethnic groups (i.e. Malays, Chinese, and Indians).
The details of the MyEIRA study have been described
elsewhere [3, 17]. In brief, patients with early RA were
identified from nine rheumatology centers throughout
Peninsular Malaysia, and for each case, a population
control was randomly selected matched by age, sex,
and residential area. All participants answered a ques-
tionnaire on a broad range of issues, including smok-
ing habits.
The InCHIANTI study is a population-based pro-
spective cohort study of residents from two areas in the
Chianti region (Tuscany, Italy). The data collection
started in September 1998 and was completed in March
2000 (baseline). A nine-year follow-up assessment of
the InCHIANTI study population was performed in the
year 2007–2008. Selection of participants and collec-
tion of DNA methylation data have been described
previously [18, 19].
DNA methylation measurement
Genome-wide methylation in peripheral blood cells from
a subset of the EIRA, EIMS and InCHIANTI cohorts
were evaluated by Illumina Infinium Human Methyla-
tion 450 BeadChip according to the manufacturer’s rec-
ommendations. Illumina Infinium Human Methylation
450 BeadChip array quantifies methylation levels at spe-
cific loci within the genome. The percentage methylation
value for a particular CpG site, which represents the
fraction of DNA with this CpG site methylated, was
calculated on a scale of 0–1, per Illumina’s recommen-
dations, using the formula:
M= M þ U þ 100ð Þ;
where M and U represent the methylated and unmethy-
lated signal intensities, respectively. Methylation data from
EIRA was published previously [12] and can be down-
loaded from Gene Expression Omnibus [GEO:GSE42861].
Genotype and smoking interaction in DNA methylation
analyzed using a linear regression model
We decided to focus on the single nucleotide polymor-
phisms (SNPs) within the major histocompatibility com-
plex (MHC region) (chr6: 29,500,000–33,500,000 (hg19))
and the 10 differentially methylated positions (DMPs),
which we identified previously to be associated with the
development of ACPA-positive RA [12]. Details of
methylation measurements have been provided previ-
ously [12]. Due to strong linkage disequilibrium of SNPs
within the MHC region, we calculated the effective
number of independent tests (Meff ) by simpleM [20].
The total 1417 SNPs investigated in the study, which
have minor allele frequency ≥0.05 and contain at least
10 individuals in each genotype group, represent 388 in-
dependent tests (Meff ).
To identify genotype and smoking interaction in DNA
methylation, we fit a linear regression model predicting
methylation at each DMP as a function of genotype,
smoking status (categorized as current smokers and
never smokers) and their interaction term, and significant
interaction was evaluated by calculating the interaction
term in the model with a stringent Bonferroni-adjusted
threshold of 0.05/(10 DMPs × 388 Meff) = 1.29 × 10
-5.
SNPs were treated with an additive minor-allele dosage
model and potential confounding factors (that is, age,
sex, and hybridization batch, and the first two principle
components of cell-type proportions estimated by cell-
specific methylation signatures as described before [12, 21])
were adjusted for in all analyses in both the EIRA and the
EIMS cohorts.
Genotype and smoking interaction in ACPA-positive RA
Two statistical models were used to evaluate the inter-
action between rs6933349 and smoking status (catego-
rized as never smokers and current smokers, or as
never smokers and ever smokers as will be specified
later) in the development of ACPA-positive RA: (1) we
performed interaction analysis by means of logistic re-
gression with adjustment for age and sex, and inter-
action was evaluated on the multiplicative scale by
calculating the interaction term in the logistic regres-
sion model, and (2) we also evaluated the interaction
between genotype and smoking in ACPA-positive RA
by departure from the additivity of effects, and bio-
logical interaction was estimated by calculating the at-
tributable proportion due to interaction (AP). AP is the
proportion of the incidence among individuals exposed
to two interacting risk factors that is attributable to the
interaction per se. AP >0 indicates that there is evi-
dence for interaction on the additive scale. Confidence
intervals for AP were estimated as described previously
[22, 23]. Additionally, relative excess risk due to inter-
action (RERI) and the synergy index (SI) were also per-
formed to evaluate interactions as described previously
[24]. Both statistical models were also adjusted for eth-
nicity in analysis of the MyEIRA cohort.
Linkage disequilibrium analysis
The measurement of linkage disequilibrium (r2) between
rs6933349 and the major RA HLA-DRB1 SE alleles were
calculated using genotype data from individuals in the
EIRA cohort. The calculation was performed by using
the “LD. Measures” function in the LDcorSV package.
Meng et al. Arthritis Research & Therapy  (2017) 19:71 Page 3 of 10
Mediation analysis
To investigate whether methylation of cg21325723 medi-
ated the rs6933349 and smoking interaction in the risk
of developing ACPA-positive RA, we assessed the effect
of including DNA methylation as a covariate in the lo-
gistical regression models relating to rs6933349, smok-
ing, and their interaction term to the ACPA-positive RA
as the outcome. The 393 individuals from the discovery
dataset analyzed, for whom we have complete informa-
tion on genotype, smoking, methylation, and RA disease.
Potential confounders (age and sex) were used for ad-
justment in all analyses.
Results
Stage 1: identification of an interaction between
genotype and smoking in DNA methylation within the
MHC region using a linear regression model
As there are extremely large numbers of different com-
binations between SNPs and CpG sites, analyses of inter-
actions, even in a relatively large cohort, are at risk of
being underpowered. Thus, we decided to focus on the
SNPs within the MHC region and the 10 DMPs, which
we identified previously to be associated with the devel-
opment of ACPA-positive RA [12]. By analyzing 393
samples from the EIRA cohort, for whom we have detailed
information on genotype, DNA methylation in blood cells,
and smoking status in each individual, we observed one sig-
nificant interaction (Bonferroni-adjusted P value < 0.05) be-
tween a SNP, rs6933349 (chr6: 31002013), and smoking
status in the DNA methylation level of the CpG site,
cg21325723 (chr6: 32402555) (Additional file 1: Figure S1).
We observed a significant association between DNA
methylation and rs6933349 (P value = 0.0048) (Fig. 2a).
However, if we stratified the samples by smoking
status, we observed significant association between the
genotype and DNA methylation among current smokers
(P value = 4.31 × 10-6), but not among never smokers
(P value = 0.52) (Fig. 2b). Among current smokers,
minor allele (rs6933349_A) carriers had a lower level
of DNA methylation at cg21325723 (Fig. 2b), which
was previously reported to be associated with increased
risk of developing ACPA-positive RA [12] (P value =
1.49 × 10-9) (Additional file 1: Figure S2). Furthermore,
among groups of individuals with a different genotype,
we observed a different relationship between methyla-
tion level and smoking status (Fig. 3). For example, the
DNA methylation level in current smokers who were
carriers of rs6933349_GA or rs6933349_AA genotypes
Stratified by smoking status
Never Smokers Current Smokers
All Individuals
Fig. 2 The associations between the genetic variant of rs6933349 and DNA methylation (cg21325723) in all individuals (a), and by smoking
status (b), in the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study. Each dot represents an individual and red horizontal bars
mark average DNA methylation levels. The statistical significance (P value) of association between genotype and DNA methylation, measured
by linear regression model, is indicated at the bottom of the plot
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was significantly lower as compared to never smokers (P
value = 0.0075 and 0.0069, respectively). No significant
difference was seen in the DNA methylation level in
current smokers and never smokers who were carriers
of rs6933349_GG genotype (Fig. 3).
Next, we sought to confirm that the interaction be-
tween genetic variation and smoking in DNA methy-
lation that was reported previously is not confounded
by the RA status. We examined the interaction
between rs6933349 and smoking in methylation of
cg21325723 separately in healthy controls and ACPA-
positive patients with RA, and observed consistent
effects in both the control-only analysis (P value =
0.0037) and the patient-only analysis (P value = 0.019).
In both analyses, we observed a significantly lower
methylation level in rs6933349_AA genotype carriers
among current smokers, while there were no associa-
tions between genotype and methylation among never
smokers (Additional file 1: Figure S3). This showed
that the combination of current smoking and minor
allele (allele A) for rs6933349 is associated with hypo-
methylation of cg21325723 and suggested the possibility
of interaction between rs6933349 and smoking in the
DNA methylation level of cg21325723, which was tested
statistically and is described later within this paper.
Considering that DNA methylation is potentially
dynamic, we further evaluated the stability of DNA
methylation of cg21325723 in an independent dataset
(the InCHIANTI cohort), in which methylation was
measured in 460 individuals at two time points sepa-
rated by 9 years. The Pearson’s correlation coefficient
for cg21325723 was 0.722 (Additional file 1: Figure S4).
This suggested that methylation in cg21325723 is mod-
erately stable over 9 years. However, the level can still
be altered, potentially by environmental risk factors for
RA, such as smoking. This is consistent with a previous
observation of familial clustering of changes in global
DNA methylation over time [25].
Stage 2: replication of an interaction between genotype
and smoking in an independent data set
We continued to replicate the finding of interaction
between rs6933349 and smoking in cg21325723 DNA
methylation in an independent dataset, the EIMS,
which is a population-based case-control study of MS.
As the methylation level of cg21325723 was not associ-
ated with the MS status (P value = 0.71), we included a
total of 139 healthy controls and 140 patients with MS,
for whom information was available on genotype,
methylation in blood, and smoking, for the replication
study. In the combined meta-analysis using data from
EIRA and EIMS, we observed significant interaction (P
value = 2.18 × 10-6) between rs6933349 and smoking
status (current vs. never smokers) in the methylation
level of cg21325723. In the relatively small EIMS co-
hort alone, the interaction was marginally significant
(P value = 0.08). Consistent with the finding from the
EIRA, among the rs6933349_AA carriers from the
Stratified by genotype (rs6933349)
rs6933349_GG rs6933349_GA rs6933349_AA
All Individuals
Fig. 3 The associations between smoking and DNA methylation (cg21325723) in all individuals (a), and in individuals with rs6933349_GG,
rs6933349_AG, or rs6933349_AA genotypes, respectively (b), in the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study. Each
dot represents an individual and red horizontal bars mark average DNA methylation levels. The statistical significance (P value) of association
between DNA methylation and smoking status, measured by Student’s t test, is indicated at the bottom of the plot
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EIMS cohort there was significantly lower methylation
in current smokers (P value = 0.024), but not in never
smokers (P value = 0.14) (Additional file 1: Figure S5).
Stage 3: novel interaction between genotype and smoking
impacting the risk of developing ACPA-positive RA
As hypo-methylation on cg21325723 has been associated
with increased risk of developing ACPA-positive RA [12]
(Additional file 1: Figure S2), we next investigated the
interaction between rs6933349 and smoking in the risk of
developing ACPA-positive RA. We addressed this ques-
tion in a larger portion of the EIRA cohort (1119 healthy
controls and 944 ACPA-positive patients with RA), which
includes the subset of 393 individuals used in the discov-
ery dataset. These analyses were performed separately for
the models with multiplicative and additive effects.
Multiplicative model
This analysis of genotype and smoking interaction in
ACPA-positive RA was evaluated on the multiplicative
scale, which accesses the interaction term in the logistic
regression model. We observed a marginally significant
interaction (multiplicative P value = 0.022 in current
smokers and 0.056 in ever smokers) between rs6933349
and smoking status in ACPA-positive RA (Table 1).
Additive model
This method is particularly relevant as it can further
determine the degree of biological interaction between
the two risk factors [26, 27]. In our analysis there was a
statistically significant gene-environment interaction
(additive P value = 0.0034 in current smokers and P
value = 0.016 in ever smokers) between rs6933349 and
smoking in the risk of developing ACPA-positive RA,
with an attributable proportion due to the interaction
(AP) value of 0.315 (95% CI 0.104 to 0.526) in current
smokers and 0.216 (95% CI 0.040 to 0.392) in ever
smokers (Table 1). We observed an increased risk of
ACPA-positive RA in individuals who were ever smokers
and carriers of rs6933349_AG/rs6933349_AA genotypes
(OR = 2.03; 95% CI 1.66 to 2.49) (Table 1, Fig. 4a). In
contrast, there was no interaction between the studied
risk factors in relation to the risk of ACPA-negative RA
(P value for AP = 0.74). Consistently, all other measures
of interaction between rs6933349 and smoking in the
risk of developing ACPA-positive RA were significant,
with the RERI value of 0.978 (95% CI 0.178 to 1.778) in
current smokers and 0.434 (95% CI 0.064 to 0.804) in
ever smokers, and the SI value of 1.869 (95% CI 1.325 to
2.413) in current smokers and 1.729 (95% CI 1.114 to
2.344) in ever smokers.
This result was further replicated in the independent
RA cohort, MyEIRA, a population-based case-control
study performed in Malaysia [17]. We observed signifi-
cant interaction (multiplicative P value = 0.035; additive
P value = 0.00027) between rs6933349 and smoking
(ever smokers) in the development of ACPA-positive
RA (Table 1) in the MyEIRA cohort. Consistent with
the finding from the EIRA, the combination of ever
smoking and the genetic variant of rs6933349_A was
Table 1 The rs6933349 genotype and smoking interaction in the risk of developing ACPA-positive RA in the EIRA and MyEIRA
studies





GG Never 1.0 (ref) 0.315 (0.104–0.526) 0.00340 0.022
GG Current 2.21 (1.74–2.82)
GA/AA Never 0.91 (0.72–1.15)
GA/AA Current 3.10 (2.38–4.05)
EIRA
GG Never 1.0 (ref) 0.216 (0.04–-0.39) 0.01600 0.056
GG Ever 1.68 (1.39–2.04)
GA/AA Never 0.91 (0.72–1.15)
GA/AA Ever 2.03 (1.66–2.49)
MyEIRA
GG Never 1.0 (ref) 0.62 (0.29–0.96) 0.00027 0.035
GG Ever 1.94 (1.30–2.90)
GA/AA Never 0.99 (0.78–1.26)
GA/AA Ever 5.14 (2.31–11.40)
AP attributable portion, EIRA Epidemiological Investigation of Rheumatoid Arthritis, MyEIRA Malaysian Epidemiological Investigation of Rheumatoid Arthritis,
ref reference
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associated with an increased risk of developing ACPA-
positive RA (Fig. 4b), whereas no significant interaction
was observed in the risk of ACPA-negative RA (additive
P value = 0.45). The fact that the EIRA is mainly com-
posed of Caucasians while the MyEIRA is a multiethnic
population of Asian descent suggests that the inter-
action between rs6933349 and smoking in the risk of
developing ACPA-positive RA is unlikely to be specific
to certain ethnic groups.
Independence from the shared epitope effect of
rs6933349 in the interaction with smoking in the risk of
developing ACPA-positive RA
The risk of developing ACPA-positive RA has been associ-
ated with interaction between smoking and HLA-DRB1
SE alleles [17, 28]. Considering the complex structure of
the MHC locus, we continued to investigate whether the
newly identified SNP, rs6933349, which interacts with
smoking to confer the risk of ACPA-positive RA, repre-
sents a novel interaction or simply reflects risk from
HLA-DRB1 SE alleles. We first examined the inter-
action between rs6933349 and smoking in the risk of
developing ACPA-positive RA by means of logistic re-
gression, with adjustment for HLA-DRB1 SE alleles in
the EIRA cohort. The multiplicative P value decreased
from 0.05 to 0.018 after the SE adjustment, suggesting
that this interaction is not dependent on HLA-DRB1 SE
alleles. Computation of the AP with adjustment for SE
alleles in the EIRA cohort also points toward significant
independent interaction between smoking and rs6933349
(AP = 0.32, P = 0.006).
Additionally, we investigated the linkage disequilibrium
(LD) between rs6933349 and known HLA-DRB1 SE alleles
(including the major RA risk alleles HLA-DRB1*04:01 and
*04:04), by calculating the r2 value between them in the
EIRA cohort. The SNP, rs6933349, which is in the region
of MHC class I (Additional file 1: Figure S1), had no
evidence of LD with HLA-DRB1 SE alleles (r2 ≤ 0.05)
(Additional file 1: Table S1), suggesting that it repre-
sents a novel gene-environment interaction in the risk
of developing ACPA-positive RA.
Stage 4: DNA methylation as a potential mediator of the
genotype and smoking interaction in the risk of
developing ACPA-positive RA
Last, we explored the role of methylation of cg21325723
as a potential mediator of the interaction between
rs6933349 and smoking in the risk of developing
ACPA-positive RA (Fig. 1a). We performed mediation
analysis [29] and modeled the relationships between
rs6933349, smoking, cg21325723 methylation, and
ACPA-positive RA in EIRA, using logistic regression.
Using the multiplicative model, we observed significant
interaction between rs6933349 and smoking in the risk
of developing ACPA-positive RA (β coefficient = 0.99;
95% CI 0.30 to 1.68; P value = 0.0051). However, after
including cg21325723 methylation as a covariate in the
regression, the interaction between rs6933349 and
smoking in relation to risk of ACPA-positive RA was
attenuated and no longer significant (β coefficient =
0.39; 95% CI -0.39 to 1.17) (P value = 0.33). This result
suggests that cg21325723 methylation may be a poten-
tial mediator of the gene-environment interaction be-
tween rs6933349 and smoking in the risk of developing
of ACPA-positive RA.
Discussion
In summary, we have identified a gene-environment
interaction between rs6933349 and smoking on the
DNA methylation level of cg21325723, which mediates
the gene-environment interaction between rs6933349
and smoking in the risk of developing ACPA-positive
RA. This gene-environment interaction represents a novel
interaction in the risk of developing ACPA-positive RA in
both Caucasian and Asian populations.
Information on smoking habits was gathered retro-
spectively by means of a questionnaire. The quality of ex-
posure information may be different in cases and controls,
which may result in recall bias. As misclassification of
smoking is likely not related to genotype, the effects of
such potential misclassification of exposure will be lim-
ited with regard to the investigated interaction between
smoking and rs6933349.
Fig. 4 Odds ratios (OR) of developing anti-citrullinated peptide
antibody-positive rheumatoid arthritis for different combinations of
smoking and rs6933349 alleles in the Epidemiological Investigation of
Rheumatoid Arthritis (EIRA) cohort (a) or the Malaysian Epidemiological
Investigation of Rheumatoid Arthritis (MyEIRA) cohort (b)
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An issue that may complicate studies involving epi-
genetics is that epigenetic modifications, such as DNA
methylation, are much more dynamic than genetic vari-
ations and can be influenced by many confounders,
such as age, sex, cell heterogeneity, and others. Al-
though we addressed this issue by adjusting for these
potential confounders in the linear regression model,
there may still be other sources of confounding that
were omitted and residual confounding that was not
fully accommodated within the linear adjustment that
we pursued. However, arguing against this idea is the
fact that the identified gene-environment interaction
between rs6933349 and smoking is not only important
in the DNA methylation level of cg21325723, but is also
important in the risk of developing ACPA-positive RA,
and this was replicated in multiple ethnic groups.
With these limitations in mind, several reasonable in-
ferences can however be made from these analyses.
First, DNA methylation can act as a mediator of gene-
environment interaction in the risk of developing
ACPA-positive RA. To the best of our knowledge, this
is the first report showing that DNA methylation can
mediate gene-environment interaction regarding the
development of a common disease. Even with the enor-
mous success in genome-wide association studies
(GWAS) of human common diseases in recent years,
the search for new genetic risk factors has not revealed
new strong effects [30]. It has been suggested that in-
teractions between different genes and between genes
and environment may explain a significant part of these
risks. In this case, the associations between genetic vari-
ants and disease phenotype may be marginally significant
and may have been neglected through a conventional
genome-wide approach [31].
Even though multiple studies suggest that gene-
environment interactions play an important role in dis-
ease susceptibility, including in RA [9, 10], a challenge
remains to provide a functional interpretation and
understand the molecular mechanism of the gene-
environment interaction in the development of disease.
DNA methylation, which can integrate both genetic
and environmental cues, can be a possible “missing
link” and is an attractive mechanism to explain the
pathogenesis of disease. Combined with the fact that
DNA methylation of cg21325723 can also integrate
other RA genetic risk variants in the MHC class II
locus [12], it is a possibility that DNA methylation is
more proximal to the RA pathogenesis than genetic
variations and this makes it a good candidate for thera-
peutic targets.
Second, even though we focused our study on the
SNPs within the MHC region and selected CpG sites
based on previous work, the success of identifying a
CpG site, with methylation that mediates a novel
interaction between genotype and smoking in the risk
of developing ACPA-positive RA, suggests that this
type of epigenetic regulation may be more common
than currently acknowledged, and the findings reported
here may simply be the “tip of the iceberg”. However, a
challenge remains in genome-wide study of this issue,
considering the extremely large number of combinations
between SNPs and CpGs. Thus, further methodological
work using advanced statistical methods for genome-wide
evaluation, together with larger sample sizes and meta-
analysis in independent studies, is important.
Third, the understanding of various possibilities of
downstream epigenetic regulation explaining the detailed
mechanisms awaits further study. Considering the critical
role of DNA methylation in regulating gene expression, an
attractive hypothesis is the epigenetic regulation of HLA
gene expression, which in combination with particular
HLA-DR gene products may be an important factor in ex-
aggerated epitope presentation in RA. The altered DNA
methylation profile within the MHC class II cluster in
ACPA-positive RA, which may affect assembly, expression
and peptide loading of HLA genes, would determine
the functional capacity of RA-associated HLA class II
molecules [32, 33] during presentation of autoantigen-
derived peptides to T cells able to drive disease-
inducing adaptive immunity (for further details of this
scenario and its T and B cell specificities, see references
[34–36]). In this scenario, it is important to identify a
target HLA gene that has expression regulated by DNA
methylation of cg21325723.
Finally, the approach presented here also demonstrates
that it might be feasible to perform an integrated genetic
and epigenetic analysis to identify genetic risk alleles
for disease that are not found by conventional analysis.
The association between the SNP, rs6933349, and
methylation at cg21325723 was not genome-wide sig-
nificant without considering the smoking interaction
(Fig. 2a), and was neglected through a conventional
genome-wide approach [12]. Given the data here,
showing that part of genetic risk is mediated epigeneti-
cally, and also that epigenetic changes may integrate
genetic and environmental effects, the augmentation of
genetic studies with epigenetic analysis promises to il-
luminate hereditary risk that is otherwise opaque when
considering genotype in isolation. Through identifying
new risk factors and revealing the role of DNA methy-
lation as mediator of genotype and smoking interaction
in the development of ACPA-positive RA, this strategy
will contribute towards understanding the mechanism
of common disease.
Conclusions
In conclusion, we identified one significant gene-en-
vironment interaction between rs6933349 and smoking in
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the DNA methylation levels of cg21325723, which has
been shown previously to be associated with the risk of
developing ACPA-positive RA. Additionally, we show that
the gene-environment interaction between rs6933349 and
smoking represents a novel interaction that confers the
risk of developing ACPA-positive RA in different ethnic
groups, and this gene-environment interaction is mediated
through DNA methylation of cg21325723.
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